<DOC>
	<DOCNO>NCT01271426</DOCNO>
	<brief_summary>To determine whether complement factor H ( CFH ) age-related maculopathy susceptibility 2 ( ARMS2 ) genotypes pharmacogenetic effect treatment polypoidal choroidal vasculopathy ( PCV ) ranibizumab .</brief_summary>
	<brief_title>Response Ranibizumab Polypoidal Choroidal Vasculopathy ( PCV ) SNPs</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Clinical diagnosis Polypoidal choroidal vasculopathy must injection Ranibizumab</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Polypoidal Choroidal Vasculopathy</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>